SCHEMBL389739

SCHEMBL389739

C1=C2CCCN2CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL368150 0.92 MAPT (0.37)
SCHEMBL29941222 0.90 MAPT (0.35)
SCHEMBL2795198 0.90 MAPT (0.35)
SCHEMBL9042088 0.90
SCHEMBL497532 0.90 MAPT (0.38)
SCHEMBL23661070 0.87 MAPT (0.37)
SCHEMBL29780367 0.87 MAPT (0.37)
SCHEMBL497034 0.87 MAPT (0.37)
SCHEMBL497686 0.87 MAPT (0.37)
SCHEMBL11814787 0.86 MAPT (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376104-A1 Bcl-2 Inhibitors BEIGENE LTD. (KY) 2024-11-14 US claimed
EP-3788042-A1 BCL-2 INHIBITORS BeiGene, Ltd. (KY) 2021-03-10 EP claimed
CN-112437772-A Bcl-2 inhibitors 百济神州有限公司 2021-03-02 CN claimed
CN-110494433-A Bruton's tyrosine kinase inhibitor LIAO XIBIN 2019-11-22 CN claimed
US-7521159-B2 Multicolor electronic paper XEROX CORPORATION (US) 2009-04-21 US claimed
US-20060222973-A1 Multicolor electronic paper XEROX CORPORATION 2006-10-05 US claimed
JP-2002543078-A 2002-12-17 JP claimed
EP-1091959-A1 NOVEL PYRROLO-(3,4-B)QUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS A MEDICAMENT MACEF (FR) 2001-04-18 EP claimed
WO-2000064897-A1 NOVEL PYRROLO-(3,4-B)QUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS A MEDICAMENT MACEF (FR) 2000-11-02 WO claimed
EP-0172692-B1 HEXAHYDROINDOLIZINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS AND INTERMEDIATES McNeilab, Inc. (US) 1990-04-18 EP claimed
EP-0172692-A1 Hexahydroindolizine compounds, pharmaceutical compositions and methods and intermediates McNeilab, Inc. (US) 1986-02-26 EP claimed
US-4572911-A ANTISECRETORY AND ANTIDEPRESSANT AGENTS MCNEILAB, INC. (US) 1986-02-25 US claimed
US-12516053-B2 Bcl-2 inhibitors BEONE MEDICINES I GMBH (CH) 2026-01-06 US disclosed
EP-4545515-A1 BCL-2 INHIBITORS BeiGene Switzerland GmbH (CH) 2025-04-30 EP disclosed
US-20240376104-A1 Bcl-2 Inhibitors BEIGENE LTD. (KY) 2024-11-14 US disclosed
US-12077536-B2 BCL-2 inhibitors BEIGENE, LTD. (KY) 2024-09-03 US disclosed
EP-0127048-A2 Optically active diphenyl ether derivatives BAYER AG (DE) 1984-12-05 EP disclosed
EP-0041661-B1 PREPARATION OF INTERMEDIATES OF CARBAPROSTACYCLINES SCHERING AKTIENGESELLSCHAFT (DE) 1984-07-18 EP disclosed
EP-0062902-A1 2,3,4-Trinor-m-inter-phenylene-prostaglandin derivatives, their preparation and pharmaceutical compositions CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) 1982-10-20 EP disclosed
EP-0009658-B1 PROCESS FOR THE PREPARATION OF OXALYL CHLORIDE BAYER AG (DE) 1981-08-26 EP disclosed